OpGen – Consensus Indicates Potential 105.2% Upside

DirectorsTalk Interviews

OpGen found using ticker (OPGN) have now 2 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 7 and 4 calculating the average target price we see 5.5. Now with the previous closing price of 2.68 this would imply there is a potential upside of 105.2%. There is a 50 day moving average of 2.49 and the 200 day moving average is 2.2. The market cap for the company is $85m. Visit the company website at: http://www.opgen.com

OpGen, a precision medicine company, engages in developing molecular information products and services in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company’s products include Acuitas AMR Gene Panel, a vitro diagnostic test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance in urine specimens or bacterial colonies isolated from urine and other body sites; and QuickFISH and PNA FISH products, which are FDA-cleared and CE-marked diagnostic test designed to detect pathogens in positive blood cultures. In addition, it offers Acuitas Lighthouse informatics systems, a cloud-based HIPAA compliant informatics offerings, which combine clinical lab test results with patient and hospital information, and provide analytics and insights to enable manage MDROs in the hospital and patient care environment. OpGen has a strategic collaboration with the New York State Department of Health to develop a solution to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Gaithersburg, Maryland.

Share on:
Find more news, interviews, share price & company profile here for:

    HUTCHMED showcases new oncology data at ASCO 2025

    HUTCHMED (China) Limited is set to unveil groundbreaking data on key cancer therapies at the 2025 ASCO Annual Meeting, highlighting promising advancements in NSCLC and solid tumors.

    Ilika launches £3.8m fundraise including £0.5m Retail Offer

    Ilika Plc has successfully closed its accelerated bookbuild, raising approximately £3.3 million to enhance solid-state battery technology and commercial growth.

    Nuformix raises £210,000 to advance NXP002 and US Orphan Drug Application

    Nuformix plc (LON:NFX) aims to raise £210,000 through a conditional placing to advance its NXP002 inhalation treatment for IPF and PPF.

    Likewise grants over 3.1m shares under 2025 SAYE scheme

    Likewise Group plc (LON:LIKE) has successfully closed its 2025 Save As You Earn Scheme, granting options to 69 employees on over 3.1 million shares.

    Zotefoams reports record £50.7m revenue in strong start to 2025

    Zotefoams Plc reports strong sales growth of 8% and record revenue for the first four months of 2025, showcasing a successful strategic pivot into key markets.

    Ilika announces £3.5m fundraise via Placing and Retail Offer

    Ilika Plc, a leader in solid-state battery technology, plans to raise approximately £3.0 million through a new share placing and a retail offer for shareholders.

      Search

      Search